Study S001252

Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06797869
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 142
Start: 2025-01-29
Primary completion: 2026-06-26
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy
Interventions: DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1306-9422; OTHER:2023-509662-38; NIH:2023

Registered primary outcomes

Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS) [From baseline (week 0) to end of treatment (week 32)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.